The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: The end of the 'silo hypothesis'

Current Opinion in Infectious Diseases

Volumn 20, Issue 4, 2007, Pages 399-407

  Rubin, Robert H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allograft; Cytokine; Cytomegalovirus; Ganciclovir

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ALLOGRAFT; CANCER PATIENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HUMAN; HYPOTHESIS; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; REVIEW;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION;

EID: 34347401878     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328285a358     Document Type: Review

References (47)

1. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, editors. Infection in the organ transplant recipient, 4th ed. New York: Kluwer/ Plenum; 2002. pp. 573-680.
2. Humar A, Malkan G, Moussa G, et al. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000; 181:1450-1453.
3. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17:357-361.
4. Nebbia G, Mattes FM, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007; 13:130-135. Informative review on CMV.
5. Carstens J, Andersen HK, et al. Cytomegalovirus infection in renal transplant recipients. Transpl Infect Dis 2006; 8:203-212.
6. Lemstrom KB, Bruning JH, Bruggeman CA, et al. Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation 1994; 90:1969-1978.
7. Humar A, Gillingham KJ, et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68:1879-1883.
8. Hussain T, Burch M, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007; 115:1798-1805.
9. Li L, Chaudhuri A, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11:187-195. Interesting review on determining the longevity of the allograft.
10. Stoica SC, Cafferty F, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006; 25:420-425.
11. Rubin RH. Infectious disease complications of renal transplantation [clinical conference]. Kidney Int 1993; 44:221-236.
12. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322:1175-1182.
13. Chou S. Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis 1990; 12 (Suppl 7):S727-S736.
14. Chou SW. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients. J Infect Dis 1989; 160:16-21.
15. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-2036.
16. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181:717-720.
17. Emery V, Sabin C, Cope A, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-2036.
18. Griffiths P, Cope A, Hassan-Walker A, Emery V. Diagnostic approach to cytomegalovirus infection in bone marrow and organ transplantation. Transpl Infect Dis 1999; 1:179-186.
19. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58:675-680.
20. Stein J, Volk HD, Liebenthal C, et al. Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/ promoter in immature monocytic cells. J Gen Virol 1993; 74:2333-2338.
21. Prosch S, Staak K, Stein J, et al. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNF-alpha is mediated via induction of NFκB. Virology 1995; 208:107-116.
22. Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994; 343:268-269.
23. Mutimer D, Mirza D, Shaw J, et al. Enhanced (cytomegalovirus) viral replication associated with septic bacterial complications in liver transplant recipients. Transplantation 1997; 63:1411-1415.
24. Mutimer DJ, Shaw J, O'Donnell K, Elias E. Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure. Liver Transpl Surg 1997; 3:506-512.
25. Kutza AS, Muhl E, Hackstein H, et al. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998; 26:1076-1082.
26. Ho M. Cytomegalovirus infection in patients with bacterial sepsis [editorial; comment]. Clin Infect Dis 1998; 26:1083-1084.
27. Reinke P, Prosch S, Kern F, Volk H. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Trans Infect Dis 1999; 1:157-164.
28. Quinnan GV Jr, Kirmani N, Rook AH, et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982; 307:7-13.
29. Rook AH, Quinnan GV Jr, Frederick WJ, et al. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med 1984; 76:385-392.
30. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78:1373-1380.
31. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731-1735.
32. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53:68-72.
33. Evans PC, Soin A, Wreghitt TG, et al. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000; 69:30-35.
34. Rubin RH, Cosimi AB, Tolkoff-Rubin NE, et al. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977; 24:458-464.
35. Chou SW. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986; 314:1418-1423.
36. Grundy JE, Super M, Lui S, et al. The source of cytomegalovirus infection in seropositive renal allograft recipients is frequently the donor kidney. Transplant Proc 1987; 19:2126-2128.
37. Grundy JE, Lui SF, Super M, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2:132-135.
38. Nordoy I, Muller F, et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 2006; 181:51-57.
39. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462-1470.
40. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-66.
41. Valantine H. Role of CMV in transplant coronary artery disease and survival after heart transplantation. Transpl Infect Dis 1999; 1:25-30.
42. Simmons R, Weil R, Tallent M, et al. Do mild infections trigger the rejection of renal allografts? Transplant Proc 1970; 2:419-423.
43. Rubin RH. Cytomegalovirus disease and allograft loss after organ transplantation [editorial]. Clin Infect Dis 1998; 26:871-873.
44. Plotkin SA, Starr SE, Friedman HM, et al. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 1990; 12 (Suppl 7):S827-S838.
45. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991; 114:525-531.
46. Torres HA, Kontoyiannis DP, et al. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. Eur J Cancer 2005; 41:2268-2279.
47. Korkmaz M, Kunefeci G, et al. The role of early colonoscopy in CMV colitis of transplant recipients. Transplant Proc 2005; 37:3059-3060.